Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide

    Phase 3 · Research guide

    Retatrutide Phase 3 Research Guide

    Updated October 20, 2026: added the published papers' numbers.

    Every published trial, every dose, and what the data says about running it well.

    Retatrutide's phase 3 results were published in September 2026, TRIUMPH-1 in NEJM and TRIUMPH-2 in The Lancet. This card puts the trial titration and results by dose in one place.

    01 / TITRATION

    How the trials titrated

    STEP 01

    2mg

    weeks 1-4

    20 units

    STEP 02

    4mg

    weeks 5-8

    40 units

    STEP 03

    6mg

    weeks 9-12

    60 units

    STEP 04

    9mg

    weeks 13-16

    90 units

    STEP 05

    12mg

    week 17 onward

    120* units

    Every arm started at 2mg once weekly and stepped up every four weeks. Nobody in the 12mg group reached 12mg until around week 17. Lower-dose arms stopped climbing at their target (4mg or 9mg).

    Units assume 10 mg per mL on a U-100 insulin syringe. 2 mg was only ever a starting step. No trial kept anyone on 2 mg, so there's no 2 mg result.

    02 / STARTING DOSE

    Start at 2 mg. The trials tested what happens if you don't.

    Nausea · titrating to 8 mg (phase 2)

    17%

    started at 2 mg

    60%

    started at 4 mg

    Vomiting · titrating to 8 mg (phase 2)

    6%

    started at 2 mg

    26%

    started at 4 mg

    Same target dose, same drug. Starting one step higher roughly tripled nausea. In the 4 mg arms it doubled, 18% versus 36%. Most side effects clustered during dose increases, which is why the four-week holds exist.

    03 / RESULTS

    Weight loss by dose at 80 weeks

    DoseTRIUMPH-1 if they stayed on itTRIUMPH-1 counting everyone who startedTRIUMPH-2 if they stayed on itTRIUMPH-2 counting everyone who started
    4mg19.0%17.6%12.7%11.9%
    9mg25.9%23.7%19.1%16.8%
    12mg28.3%25.0%20.8%18.8%
    Placebo2.2%3.9%4.0%5.1%

    Lilly's releases lead with the number for people who stayed on the drug (the efficacy estimand). The NEJM and Lancet papers lead with the number for everyone who started, including people who stopped (the treatment-regimen estimand).

    If you're insulin resistant, prediabetic or diabetic, TRIUMPH-2 is the trial that describes you. In the diabetic trial, going from 9mg to 12mg added only 1.7 points (2.0 counting everyone who started).

    In TRIUMPH-1, 45.3% of the 12 mg group lost 30% or more of their body weight.

    04 / TIMING

    When the weight comes off

    12 mg · Week 2417.5%
    12 mg · Week 4824.2%
    12 mg · Week 8028.3% (25.0% counting everyone who started)

    Weeks 24 and 48 from the phase 2 trial, week 80 from TRIUMPH-1. The 12 mg curve was still dropping at week 48 with no plateau. Judge it at months, not weeks: the first 16 weeks are mostly titration.

    05 / TRIALS

    Every trial so far, at the top dose

    TrialWho was in itPeopleLengthIf they stayed on itCounting everyone who started
    Phase 2Obesity33848 weeks24.2%—
    TRIUMPH-1Obesity, no diabetes2,33980 weeks28.3%25.0%
    TRIUMPH-2Obesity + type 2 diabetes1,15280 weeks20.8%18.8%
    TRIUMPH-3Severe obesity + heart disease1,94980 weeks22.6%—
    TRIUMPH-4Obesity + knee osteoarthritis44568 weeks28.7%23.7%

    06 / SAFETY

    Side effects, by the numbers

    11-18%

    quit the 12 mg dose over side effects. 11.3% in TRIUMPH-1, 18.2% in TRIUMPH-4. Placebo was 4-5%.

    7-21%

    dysesthesia at 12 mg, an altered skin sensation unique to this drug. 7.3% in TRIUMPH-2, 20.9% in TRIUMPH-4.

    +6.7

    beats per minute peak resting heart rate rise at 12 mg in phase 2, highest around week 24, easing after.

    GI effects (nausea, vomiting, diarrhea, constipation) were the most common, mostly mild to moderate, and concentrated during dose increases. Lower doses dropped out less: 4.1% at 4 mg in TRIUMPH-1, below placebo.

    07 / CONCENTRATION

    Reconstitution math

    10 mg vial + 1 mL bacteriostatic water = 10 mg per mL. On a U-100 insulin syringe, 10 units = 1 mg. Same concentration with 20 mg + 2 mL or 30 mg + 3 mL.

    DoseU-100 syringe units at 10 mg per mL
    2 mg20 units
    4 mg40 units
    6 mg60 units
    9 mg90 units
    12 mg120 units*

    *120 units is more than a 1 mL syringe holds, and more than one 10 mg vial contains. At the 12 mg step, a stronger mix avoids splitting: 30 mg vial + 2 mL = 15 mg per mL, so 12 mg = 80 units. Recheck the math every time you change vial size or water volume.

    08 / MONITORING

    What's worth tracking

    • Body weight and waist, weekly
    • Resting heart rate, weekly
    • A1C and fasting glucose
    • Lipid panel
    • CMP (kidney and liver)
    • Lipase

    Get a baseline before starting, then recheck around every three months. Weight, waist, A1C, glucose, blood pressure and lipids are the markers the trials themselves reported.

    Class warnings. Approved drugs in the same class carry label warnings for pancreatitis, gallbladder disease and thyroid C-cell tumors (seen in rodents). Severe stomach pain that doesn't let up, especially spreading to the back, needs medical attention, not another week of waiting it out.

    09 / STATUS

    Where it stands

    1. Now

      not approved in any country

    2. Q1 2027

      Lilly files the BLA with the FDA

    3. +10-12 months

      standard FDA review

    4. Late 2027

      earliest realistic approval

    Download the 2-page PDF

    Unlock the full card

    Two-page research guide. Results by dose, side effects, reconstitution math and what to track. Free.

    No spam, unsubscribe anytime

    For research and educational purposes only. Retatrutide is investigational and not approved for human use in any jurisdiction. Not medical advice.